Carlos A. Sariol to Puerto Rico
This is a "connection" page, showing publications Carlos A. Sariol has written about Puerto Rico.
Connection Strength
0.593
-
Sariol CA, Serrano-Collazo C, Ortiz EJ, Pantoja P, Cruz L, Arana T, Atehortua D, Pabon-Carrero C, Espino AM. Limited Impact of Delta Variant's Mutations on the Effectiveness of Neutralization Conferred by Natural Infection or COVID-19 Vaccines in a Latino Population. Viruses. 2021 11 30; 13(12).
Score: 0.149
-
Sariol CAA, Pantoja P, Serrano-Collazo C, Rosa-Arocho T, Armina-Rodr?guez A, Cruz L, Stone ETT, Arana T, Climent C, Latoni G, Atehortua D, Pabon-Carrero C, Pinto AKK, Brien JDD, Espino AMM. Function Is More Reliable than Quantity to Follow Up the Humoral Response to the Receptor-Binding Domain of SARS-CoV-2-Spike Protein after Natural Infection or COVID-19 Vaccination. Viruses. 2021 09 30; 13(10).
Score: 0.147
-
Kanthaswamy S, Oldt RF, Ng J, Smith DG, Mart?nez MI, Sariol CA. Determination of major histocompatibility class I and class II genetic composition of the Caribbean Primate Center specific pathogen-free rhesus macaque (Macaca mulatta) colony based on massively parallel sequencing. J Med Primatol. 2018 12; 47(6):379-387.
Score: 0.117
-
Kanthaswamy S, Oldt RF, Ng J, Ruiz-Lambides AV, Maldonado E, Mart?nez MI, Sariol CA. Population Genetic Structure of the Cayo Santiago Colony of Rhesus Macaques (Macaca mulatta). J Am Assoc Lab Anim Sci. 2017 Jul 01; 56(4):396-401.
Score: 0.109
-
Sariol CA, Arana T, Maldonado E, Gerald M, Gonzalez-Martinez J, Rodriguez M, Kraiselburd EN. Herpes B-virus seroreactivity in a colony of Macaca mulatta: data from the Sabana Seca Field Station, a new specific pathogen-free program. J Med Primatol. 2005 Feb; 34(1):13-9.
Score: 0.046
-
Sirivichayakul C, Barranco-Santana EA, Esquilin-Rivera I, Oh HM, Raanan M, Sariol CA, Shek LP, Simasathien S, Smith MK, Velez ID, Wallace D, Gordon GS, Stinchcomb DT. Safety and Immunogenicity of a Tetravalent Dengue Vaccine Candidate in Healthy Children and Adults in Dengue-Endemic Regions: A Randomized, Placebo-Controlled Phase 2 Study. J Infect Dis. 2016 May 15; 213(10):1562-72.
Score: 0.025